EA
UTHR icon

Emerald Advisers’s United Therapeutics UTHR Stock Holding History

Emerald Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$796K Buy
1,469
+400
+37% +$225K 0.02% 159
2026
Q1 		$634K Hold
1,069
– – 0.02% 163
2025
Q4 		$521K Sell
1,069
-47
-4% -$21.9K 0.02% 168
2025
Q3 		$468K Buy
1,116
+249
+29% +$83.7K 0.02% 189
2025
Q2 		$249K Buy
867
+15
+2% +$4.48K 0.01% 212
2025
Q1 		$263K Sell
852
-1,061
-55% -$364K 0.01% 195
2024
Q4 		$675K Sell
1,913
-19
-1% -$6.98K 0.03% 155
2024
Q3 		$692K Buy
+1,932
New +$653K 0.03% 155
2023
Q4 		– Sell
-1,376
Closed -$311K – 253
2023
Q3 		$311K Sell
1,376
-4,621
-77% -$1.06M 0.02% 189
2023
Q2 		$1.32M Sell
5,997
-72,089
-92% -$16M 0.06% 140
2023
Q1 		$17.5M Sell
78,086
-16,356
-17% -$4.03M 0.84% 49
2022
Q4 		$26.3M Buy
94,442
+1,189
+1% +$300K 1.27% 23
2022
Q3 		$19.5M Sell
93,253
-66,840
-42% -$14.9M 1.01% 35
2022
Q2 		$37.7M Sell
160,093
-43,266
-21% -$8.8M 1.94% 3
2022
Q1 		$36.5M Buy
203,359
+17,402
+9% +$3.32M 1.39% 18
2021
Q4 		$40.2M Sell
185,957
-3,850
-2% -$756K 1.48% 12
2021
Q3 		$35M Buy
189,807
+2,347
+1% +$462K 1.27% 21
2021
Q2 		$33.6M Sell
187,460
-7,068
-4% -$1.35M 1.23% 23
2021
Q1 		$32.5M Sell
194,528
-18,426
-9% -$3.07M 1.17% 20
2020
Q4 		$32.3M Buy
212,954
+19,992
+10% +$2.62M 1.07% 26
2020
Q3 		$19.5M Sell
192,962
-5,199
-3% -$570K 0.8% 52
2020
Q2 		$24M Buy
198,161
+68,104
+52% +$7.66M 1.04% 31
2020
Q1 		$12.3M Buy
+130,057
New +$12.4M 0.71% 53
2015
Q4 		– Sell
-6,749
Closed -$886K – 335
2015
Q3 		$886K Sell
6,749
-60
-0.9% -$9.62K 0.05% 262
2015
Q2 		$1.18M Sell
6,809
-6,240
-48% -$1.12M 0.06% 236
2015
Q1 		$2.13M Sell
13,049
-7,160
-35% -$1.09M 0.11% 210
2014
Q4 		$2.62M Buy
+20,209
New +$2.6M 0.14% 187

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Emerald Advisers's UTHR Position: Q2 2026 in Review

Emerald Advisers increased its United Therapeutics (UTHR) stake by 37% in Q2 2026, buying an estimated $225K and bringing the position to 1,469 shares worth $796K. The position accounts for 0.02% of the portfolio, ranked #159.

Emerald Advisers first reported a position in UTHR in Q4 2014 and has held it in 27 quarters since. The position peaked at $40.2M in Q4 2021. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Emerald Advisers held 1,469 shares of United Therapeutics worth $796K as of Q2 2026.
  • Emerald Advisers bought 400 United Therapeutics shares in Q2 2026, an estimated $225K.
  • United Therapeutics made up 0.02% of Emerald Advisers's portfolio in Q2 2026, its #159 holding.
  • Emerald Advisers first reported a position in United Therapeutics in Q4 2014 and has held it in 27 quarters since.
  • Emerald Advisers's United Therapeutics position peaked at $40.2M in Q4 2021.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.